Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
The proposed study is designed to test a novel dosing paradigm that would facilitate the
treatment of anemia in CKD patients on dialysis. Anemic patients on hemo and peritoneal
dialysis who have achieved and maintained target hemoglobin (Hb) on every other week (Q2W)
dosing of darbepoetin alfa will have the dosing interval extended to once monthly (QM)
dosing.